Pegylated TNF-α Receptor Does Not Prevent Acute Graft-versus-Host Disease in the Dog Leukocyte Antigen-Nonidentical Unrelated Canine Model

Biology of Blood and Marrow Transplantation

Volumn 12, Issue 11, 2006, Pages 1198-1200

  Graves, Scott S ^a   Ryoo, Hun Mo ^a   Sale, George ^a,b   Storb, Rainer ^a,b   Cowan, Laine A ^c   Matsuda, Katherine ^c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERTOLIZUMAB PEGOL; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; LEUKOCYTE ANTIGEN; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TSUKUBAENOLIDE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT VERSUS HOST DISEASE; ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; CYTOTOXICITY; DOG; DRUG BLOOD LEVEL; EXPERIMENTAL MODEL; GASTROINTESTINAL DISEASE; GRAFT SURVIVAL; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES VIRUS; HERPES VIRUS INFECTION; HISTOPATHOLOGY; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; LETTER; MONOCYTE; NONHUMAN; TREATMENT FAILURE; TREATMENT OUTCOME; WEIGHT REDUCTION; WHOLE BODY RADIATION;

ANIMALS; CHIMERISM; DOGS; GRAFT VS HOST DISEASE; MODELS, ANIMAL; POLYETHYLENE GLYCOLS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 33750510116     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.07.003     Document Type: Letter

References (14)

1. Brown G.R., Lee E., and Thiele D.L. TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class II-disparate (C57BL/6J→C57BL/6J × bm12)F1 mice. J Immunol 168 (2002) 3065-3071
2. Teshima T., Ordemann R., Reddy P., et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 8 (2002) 575-581
3. Couriel D., Saliba R., Hicks K., et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 104 (2004) 649-654
4. Chiang K.Y., Abhyankar S., Bridges K., Godder K., and Henslee-Downey J.P. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 73 (2002) 665-667
5. Hervé P., Flesch M., Tiberghien J., et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor α antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 79 (1992) 3362-3368
6. Kubetzko S., Sarkar C.A., and Pluckthun A. Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Mol Pharmacol 68 (2005) 1439-1454
7. Edwards III C.K. PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases. (review). Ann Rheum Dis 58 suppl 1 (1999) I73-I81
8. Storb R., Kolb H.J., Graham T.C., Kolb H., Weiden P.L., and Thomas E.D. Treatment of established graft-versus-host disease in dogs by antithymocyte serum or prednisone. Blood 42 (1973) 601-609
9. Yu C., Linsley P., Seidel K., et al. Cytotoxic T lymphocyte antigen 4-immunoglobulin fusion protein combined with methotrexate/cyclosporine as graft-versus-host disease prevention in a canine dog leukocyte antigen-nonidentical marrow transplant model. Transplantation 69 (2000) 450-454
10. Van den Brande J.M., Braat H., van den Brink G.R., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124 (2003) 1774-1785
11. Bendele A.M., McComb J., Gould T., Frazier J., Chlipala E., Seely J., Kieft G., and Edwards III C.K. Effects of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) alone and in combination with methotrexate in adjuvant arthritic rats. Clin Exp Rheumatol 17 5 (1999) 553-560 Sep-Oct
12. Yu C., Storb R., Deeg H.J., et al. Tacrolimus (FK506) and methotrexate regimens to prevent graft-versus-host disease after unrelated dog leukocyte antigen (DLA) nonidentical marrow transplantation. Bone Marrow Transplant 17 (1996) 649-653
13. Yu C., Seidel K., Nash R.A., et al. Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood 91 (1998) 2581-2587
14. n polymorphisms to determine the origin of blood cells after allogeneic canine marrow grafting. Transplantation 58 (1994) 701-706